Trial
NCT03267680
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI); Brooklyn ImmunoTherapeutics, LLC
Condition
Cervical Squamous Cell Carcinoma In Situ
Intervention
Cyclophosphamide
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-13